Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Abdominal Obesity, Growth Hormone Deficiency
Interventions
Growth hormone releasing hormone (GHRH) 1-44, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation

NCT01778712
Conditions
Menopause, Visceral Adipose Tissue Accumulation, Abdominal Obesity, Obesity, Overweight
Interventions
Multi-level intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
42 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metabolic Syndrome
Interventions
Rimonabant, Placebo (for Rimonabant), Mild hypocaloric diet
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Obesity, Overweight, Fatty Liver, Metabolic Syndrome X
Interventions
Almond, Cereal Bar
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Obesity
Interventions
Pediatric Obesity Intervention (STANDARD), Pediatric Obesity Intervention + High Activity (ADDED)
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
7 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Obesity, Cardiovascular Diseases, Metabolic Syndrome, Metabolic Disease
Interventions
20Lighter Program
Other
Lead sponsor
20Lighter
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Cheyenne, Wyoming
Conditions
Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

NCT02833415
Conditions
Obesity, Visceral
Interventions
[U-13C3] glycerol, Empagliflozin, Placebo (for Empagliflozin)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
30 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metabolic Syndrome
Interventions
Exercise Training
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Dilworth, Minnesota • Columbus, Ohio + 1 more
Conditions
Obesity, Weight Loss
Interventions
1170-1870 kcal/day liquid diet, Gastric bypass surgery, Biopsy.visceral adipose tissue, Biopsy.omental adipose tissue, Biopsy. subcutaneous abdominal adipose tissue, Blood sample
Behavioral · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Obesity, Metabolic Syndrome X
Interventions
Metformin, Orlistat, Topiramate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
40 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Obesity, Metabolic Disease, Eating Behavior, Adiposity, Sleep, Physical Activity
Interventions
Not listed
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 24 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Austin, Texas
Conditions
Visceral Obesity, Insulin Resistance
Interventions
Water-only fasting
Other
Lead sponsor
TrueNorth Health Foundation
Other
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Santa Rosa, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620
Conditions
Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
35 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Completed No phase listed Observational Accepts healthy volunteers

Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin

NCT00412269
Conditions
Menopause
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
47 Years to 52 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed No phase listed Observational Accepts healthy volunteers

Regional Fat Depots and Insulin Resistance

NCT01336777
Conditions
Obesity, Insulin Resistance, Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
39 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Stanford, California
Conditions
Schizophrenia, Metabolic Syndrome X, Insulin Resistance
Interventions
Switch, Control
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Conditions
Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Interventions
GLP-1 receptor agonist
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
55 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Conditions
HIV, HIV-Infections, HIV-1-infection, HIV I Infection, HIV Lipodystrophy, HIV Infection Primary, HIV-Associated Lipodystrophy, HIV Disease Progression, Lipohypertrophy, Liver Diseases, NAFLD, NASH, Liver Fibrosis, Hepatic Fibrosis, Waist Circumference, BMI, Ectopic Fat, Liver Fat, Hepatic Steatosis
Interventions
Diagnostic Test, HIV Anti-retroviral Background Therapy
Diagnostic Test · Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Miami Beach, Florida + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Impacts of Aronia on Inflammation and the Gut Microbiome

NCT04128839
Conditions
Metabolic Syndrome, Inflammation, Hypertriglyceridemia, Obesity
Interventions
Aronia berry juice, Sham comparator
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bozeman, Montana